HQY analyst estimates
HealthEquity (HQY) analyst ratings, the average price target and its range, and every firm's latest call.
HQY analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 21, 2026 | BMO Capital | HealthEquity price target raised to $125 from $105 at BMO Capital | $125.00 |
| Sep 18, 2026 | Barclays | HealthEquity price target raised to $115 from $110 at Barclays | $115.00 |
| Aug 31, 2026 | Deutsche Bank | HealthEquity price target raised to $142 from $135 at Deutsche Bank | $142.00 |
| Aug 28, 2026 | Telsey Advisory | HealthEquity (HQY) Reiterated at Market Outperform by Citizens: Q2 Revenue Above Estimate | $111.00 |
| Jul 24, 2026 | BTIG | HealthEquity price target raised to $115 from $110 at BTIG | $115.00 |
| Jun 3, 2026 | RBC Capital | RBC Capital Reiterates Outperform Rating on HealthEquity, Inc (HQY) Following Mgmt Meet | $108.00 |
| Jun 1, 2026 | Wells Fargo | HealthEquity, Inc (HQY) PT Raised to $111 at Citizens on Raised FY27-28 EPS Estimates | $111.00 |
| Apr 9, 2026 | BMO Capital | HealthEquity upgraded to Outperform from Market Perform at BMO Capital | $105.00 |
| Feb 24, 2026 | BMO Capital | HealthEquity price target lowered to $85 from $100 at BMO Capital | $85.00 |
| Feb 19, 2026 | Jefferies | HealthEquity price target lowered to $108 from $120 at Jefferies | $108.00 |
| Feb 18, 2026 | Barclays | HealthEquity price target lowered to $110 from $118 at Barclays | $110.00 |
| Feb 17, 2026 | Raymond James | HealthEquity price target lowered to $100 from $120 at Raymond James | $100.00 |
| Feb 17, 2026 | UBS | HealthEquity price target lowered to $110 from $130 at BTIG | $110.00 |
| Jan 9, 2026 | Goldman Sachs | HealthEquity downgraded to Sell from Neutral at Goldman Sachs | $89.00 |
| Jan 8, 2026 | KeyBanc | HealthEquity price target raised to $125 from $120 at KeyBanc | $125.00 |
- 10 firms rate HQY: 9 buy, 0 hold, 1 sell.
- The average price target is $118.14 from 7 analysts, from $108.00 to $142.00.
Updated 2026-11-03 00:02 UTC